Bariatric surgery and T2DM improvement mechanisms: A mathematical model

Theoretical Biology and Medical Modelling

Volumn 9, Issue 1, 2012, Pages

  Toghaw, Puntip ^a,b,c   Matone, Alice ^b   Lenbury, Yongwimon ^c,d   De Gaetano, Andrea ^b,d  

^a KASETSART UNIVERSITY   (Thailand)

^b CNR   (Italy)

^c Thailand Ministry of Science and Technology   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bariatric Surgery; Diabetes; Incretins; Mathematical Model

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ARTICLE; BARIATRIC SURGERY; BIOLOGICAL MODEL; DRUG ANTAGONISM; HUMAN; INTESTINE; MATHEMATICAL PHENOMENA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TREATMENT OUTCOME;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS; INSULIN; INTESTINES; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; OBESITY; TREATMENT OUTCOME;

EID: 84860910951     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-9-16     Document Type: Article

References (87)

1. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, Arterioscler Thromb Vasc Biol 2006 26 968 976 10.1161/01.ATV.0000216787.85457.f3 16627822 (Pubitemid 43732100)
2. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Calle EE, Kaaks R, Nat Rev Cancer 2004 4 579 591 10.1038/nrc1408 15286738 (Pubitemid 39025053)
3. Abdominal obesity and metabolic syndrome. Despres JP, Lemieux I, Nature 2006 444 881 887 10.1038/nature05488 17167477 (Pubitemid 46024995)
4. Bariatric surgery: a review of procedures and outcomes. Elder KA, Wolfe BM, Gastroenterology 2007 132 2253 2271 10.1053/j.gastro.2007.03.057 17498516 (Pubitemid 46693754)
5. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrere B, Obes Surg 2009 19 217 229 10.1007/s11695-008-9696-3 18820978
6. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Hickey MS, Pories WJ, MacDonald KG, Cory KA, Dohm GL, Swanson MS, Israel RG, Barakat HA, Considine RV, Caro JF, et al. Ann Surg 1998 227 637 643 10.1097/00000658-199805000-00004 9605655 (Pubitemid 28530913)
7. Normalization of Insulin Sensitivity in the Obese Patient after Stable Weight Reduction with Biliopancreatic Diversion. Castagneto M, De Gaetano A, Mingrone G, Tacchino R, Nanni G, Capristo E, Benedetti G, Tataranni PA, Greco AV, Obes Surg 1994 4 161 168 10.1381/096089294765558755 10742775 (Pubitemid 24164175)
8. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Salehi M, Prigeon RL, D'Alessio DA, Diabetes 2011 60 2308 2314 10.2337/db11-0203 21868791
9. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. Campos GM, Rabl C, Peeva S, Ciovica R, Rao M, Schwarz JM, Havel P, Schambelan M, Mulligan K, J Gastrointest Surg 2010 14 15 23 10.1007/s11605-009-1060-y 19838759
10. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R, Diabetologia 2011 54 2506 2514 10.1007/s00125-011-2204-7 21656330
11. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E, Am J Med 2005 118 51 57 10.1016/j.amjmed.2004.08.017 15639210 (Pubitemid 40082459)
12. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G, Diabetes 2006 55 2025 2031 10.2337/db06-0068 16804072 (Pubitemid 44509976)
13. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Mingrone G, Nutr Metab Cardiovasc Dis 2008 18 574 579 10.1016/j.numecd.2008.07.004 18790374
14. Ultradian ghrelin pulsatility is disrupted in morbidly obese subjects after weight loss induced by malabsorptive bariatric surgery. Mingrone G, Granato L, Valera-Mora E, Iaconelli A, Calvani MF, Bracaglia R, Manco M, Nanni G, Castagneto M, Am J Clin Nutr 2006 83 1017 1024 16685041 (Pubitemid 44713099)
15. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G, Diabetes Care 2009 32 375 380 10.2337/dc08-1314 19033407
16. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Ferrannini E, Mingrone G, Diabetes Care 2009 32 514 520 10.2337/dc08-1762 19246589
17. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, N Engl J Med 2012 366 17 1577 1585 10.1056/NEJMoa1200111 22449317
18. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Cummings DE, Int J Obes (Lond) 2009 33 Suppl 1 33 S40
19. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E, J Clin Endocrinol Metab 2001 86 5083 5086 10.1210/jc.86.10.5083 11600590 (Pubitemid 33020569)
20. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ, Surg Obes Relat Dis 2007 3 109 115 10.1016/j.soard.2007.02.003 17386391 (Pubitemid 46444709)
21. The role of gut hormones in glucose homeostasis. Drucker DJ, J Clin Invest 2007 117 24 32 10.1172/JCI30076 17200703 (Pubitemid 46048446)
22. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR, Ann Surg 2006 243 108 114 10.1097/01.sla.0000183349.16877.84 16371744 (Pubitemid 43054062)
23. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ, Surg Obes Relat Dis 2007 3 597 601 10.1016/j.soard.2007.08.004 17936091 (Pubitemid 350091417)
24. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV, N Engl J Med 2005 353 249 254 10.1056/NEJMoa043690 16034010 (Pubitemid 41058324)
25. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Rubino F, Marescaux J, Ann Surg 2004 239 1 11 10.1097/01.sla.0000102989.54824.fc 14685093 (Pubitemid 38176365)
26. The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Rubino F, Zizzari P, Tomasetto C, Bluet-Pajot MT, Forgione A, Vix M, Grouselle D, Marescaux J, Endocrinology 2005 146 1745 1751 10.1210/en.2004-1181 15625244 (Pubitemid 40396883)
27. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Pacheco D, de Luis DA, Romero A, Gonzalez SM, Conde R, Izaola O, Aller R, Delgado A, Am J Surg 2007 194 221 224 10.1016/j.amjsurg.2006.11.015 17618808 (Pubitemid 47008973)
28. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE, Ann Surg 2008 247 968 975 10.1097/SLA.0b013e318172504d 18520224 (Pubitemid 351770417)
29. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34kg/m2: a report of 2 cases. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F, Surg Obes Relat Dis 2007 3 195 197 10.1016/j.soard.2007.01.009 17386401 (Pubitemid 46444706)
30. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J, Ann Surg 2006 244 741 749 10.1097/01.sla.0000224726. 61448.1b 17060767 (Pubitemid 44629948)
31. Wikibooks contributors, Human Physiology, 2007
32. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Girard J, Diabetes Metab 2008 34 550 559 10.1016/j.diabet.2008.09.001 19036624
33. Incretins, insulin secretion and Type 2 diabetes mellitus. Vilsboll T, Holst JJ, Diabetologia 2004 47 357 366 10.1007/s00125-004-1342-6 14968296 (Pubitemid 38491230)
34. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Meier JJ, Best Pract Res Clin Endocrinol Metab 2009 23 433 441 10.1016/j.beem.2009.03.007 19748061
35. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Nauck M, Stockmann F, Ebert R, Creutzfeldt W, Diabetologia 1986 29 46 52 10.1007/BF02427280 3514343 (Pubitemid 16162741)
36. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Mentlein R, Regul Pept 1999 85 9 24 10.1016/S0167-0115(99)00089-0 10588446 (Pubitemid 29505281)
37. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Mingrone G, Castagneto-Gissey L, Diabetes Metab 2009 35 518 523 10.1016/S1262-3636(09)73459-7 20152737
38. Central and peripheral roles of ghrelin on glucose homeostasis. Sun Y, Asnicar M, Smith RG, Neuroendocrinology 2007 86 215 228 10.1159/000109094 17898534 (Pubitemid 350073609)
39. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschop MH, D'Alessio D, Diabetes 2010 59 2145 2151 10.2337/db10-0504 20584998
40. A mathematical model of the oral glucose tolerance test illustrating the effects of the incretins. Brubaker PL, Ohayon EL, D'Alessandro LM, Norwich KH, Ann Biomed Eng 2007 35 1286 1300 10.1007/s10439-007-9274-1 17393338 (Pubitemid 46966276)
41. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Verspohl EJ, Pharmacol Ther 2009 124 113 138 10.1016/j.pharmthera. 2009.06.002 19545590
42. Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings. Dunn JP, Cowan RL, Volkow ND, Feurer ID, Li R, Williams DB, Kessler RM, Abumrad NN, Brain Res 2010 1350 123 130 20362560
43. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Gautier JF, Choukem SP, Girard J, Diabetes Metab 2008 34 Suppl 2 65 S72 18640588
44. The physiology of glucagon-like peptide 1. Holst JJ, Physiol Rev 2007 87 1409 1439 10.1152/physrev.00034.2006 17928588 (Pubitemid 350041474)
45. The incretin system and its role in type 2 diabetes mellitus. Holst JJ, Vilsboll T, Deacon CF, Mol Cell Endocrinol 2009 297 127 136 10.1016/j.mce.2008. 08.012 18786605
46. Incretin levels and effect are markedly enhanced 1month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B, Diabetes Care 2007 30 1709 1716 10.2337/dc06-1549 17416796 (Pubitemid 47036341)
47. tandards of medical care in diabetes - 2011. American Diabetes Association, Diabetes Care 2011 34 Suppl 1 11 S61 21193625
48. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L, Obesity (Silver Spring) 2008 16 298 305 10.1038/oby.2007.83 (Pubitemid 351271908)
49. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM, Am J Physiol Endocrinol Metab 2006 290 550 E559 16219666
50. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De M I, Clin Chem Lab Med 2001 39 155 159 11341750 (Pubitemid 32318480)
51. Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. Michaeli B, Berger MM, Revelly JP, Tappy L, Chiolero R, Clin Nutr 2007 26 70 77 10.1016/j.clnu.2006.06.001 17055120 (Pubitemid 46179108)
52. Gastric emptying and release of incretin hormones after glucose ingestion in humans. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B, J Clin Invest 1996 97 92 103 10.1172/JCI118411 8550855 (Pubitemid 26021698)
53. An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. Silber HE, Frey N, Karlsson MO, J Clin Pharmacol 2010 50 246 256 10.1177/0091270009341185 19940230
54. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Winther K, et al. Lancet 1995 346 397 402 10.1016/S0140-6736(95)92779-4 7623569
55. Evaluation of four mathematical models of glucose and insulin dynamics with analysis of effects of age and obesity. Walton C, Godsland IF, Proudler AJ, Felton C, Wynn V, Am J Physiol 1992 262 755 E762 1590386
56. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ, J Clin Endocrinol Metab 2003 88 2706 2713 10.1210/jc.2002-021873 12788877 (Pubitemid 36724446)
57. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ, Gastroenterology 2007 132 2131 2157 10.1053/j.gastro.2007.03.054 17498508 (Pubitemid 46711096)
58. Nutritional regulation of glucagon-like peptide-1 secretion. Tolhurst G, Reimann F, Gribble FM, J Physiol 2009 587 27 32 10.1113/jphysiol.2008.164012 19001044
59. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W, J Clin Invest 1993 91 301 307 10.1172/JCI116186 8423228 (Pubitemid 23037285)
60. Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. Tassone F, Broglio F, Destefanis S, Rovere S, Benso A, Gottero C, Prodam F, Rossetto R, Gauna C, van der Lely AJ, et al. J Clin Endocrinol Metab 2003 88 5478 5483 10.1210/jc.2003-030564 14602793 (Pubitemid 37452758)
61. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Mortensen K, Christensen LL, Holst JJ, Orskov C, Regul Pept 2003 114 189 196 10.1016/S0167-0115(03)00125-3 12832109 (Pubitemid 36773884)
62. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B, Diabetes 2004 53 654 662 10.2337/diabetes.53.3.654 14988249 (Pubitemid 38270634)
63. What do we know about the secretion and degradation of incretin hormones? Deacon CF, Regul Pept 2005 128 117 124 10.1016/j.regpep.2004.06.007 15780431 (Pubitemid 40380912)
64. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ, N Engl J Med 2002 346 1623 1630 10.1056/NEJMoa012908 12023994 (Pubitemid 34755670)
65. Gut hormones and appetite control. Hameed S, Dhillo WS, Bloom SR, Oral Dis 2009 15 18 26 10.1111/j.1601-0825.2008.01492.x 18939959
66. Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. McCowen KC, Maykel JA, Bistrian BR, Ling PR, J Endocrinol 2002 175 7 R11 10.1677/joe.0.175R007 12429053
67. Ghrelin response to carbohydrate-enriched breakfast is related to insulin. Blom WA, Stafleu A, de Graaf C, Kok FJ, Schaafsma G, Hendriks HF, Am J Clin Nutr 2005 81 367 375 15699223 (Pubitemid 43073337)
68. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M, Endocrinology 2000 141 4255 4261 10.1210/en.141.11.4255 11089560
69. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, et al. Ann Surg 1995 222 339 350 10.1097/00000658-199509000-00011 7677463
70. Neuro-modulation and bariatric surgery for type 2 diabetes mellitus. Spector D, Shikora S, Int J Clin Pract Suppl 2010 166 53 58 20377665
71. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35kg/m2. Chiellini C, Rubino F, Castagneto M, Nanni G, Mingrone G, Diabetologia 2009 52 1027 1030 10.1007/s00125-009-1333-8 19308351
72. Biliopancreatic diversion. Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A, World J Surg 1998 22 936 946 10.1007/s002689900497 9717419 (Pubitemid 28374611)
73. Mechanism for improved insulin sensitivity after gastric bypass surgery. Bikman BT, Zheng D, Pories WJ, Chapman W, Pender JR, Bowden RC, Reed MA, Cortright RN, Tapscott EB, Houmard JA, et al. J Clin Endocrinol Metab 2008 93 4656 4663 10.1210/jc.2008-1030 18765510
74. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Rubino F, Diabetes Care 2008 31 Suppl 2 290 S296 18227499
75. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, Nanni G, Holst JJ, Diabetologia 2009 52 873 881 10.1007/s00125-009-1288-9 19229515
76. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Vetter ML, Cardillo S, Rickels MR, Iqbal N, Ann Intern Med 2009 150 94 103 19153412
77. Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents. Kindel TL, Martins PJ, Yoder SM, Jandacek RJ, Seeley RJ, D'Alessio DA, Obici S, Tso P, Obesity (Silver Spring) 2011 19 380 387 10.1038/oby.2010.263
78. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K, J Clin Endocrinol Metab 2003 88 1594 1602 10.1210/jc.2002-021309 12679444 (Pubitemid 36623375)
79. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E, Ann Surg 2004 240 236 242 10.1097/01.sla.0000133117.12646.48 15273546 (Pubitemid 38963013)
80. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. Bose M, Teixeira J, Olivan B, Bawa B, Arias S, Machineni S, Pi-Sunyer FX, Scherer PE, Laferrere B, J Diabetes 2010 2 47 55 10.1111/j.1753-0407.2009.00064.x 20676394
81. Early changes in incretin secretion after laparoscopic duodenal-jejunal bypass surgery in type 2 diabetic patients. Lee HC, Kim MK, Kwon HS, Kim E, Song KH, Obes Surg 2010 20 1530 1535 10.1007/s11695-010-0248-2 20803098
82. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, et al. J Clin Endocrinol Metab 2008 93 2479 2485 10.1210/jc.2007-2851 18430778 (Pubitemid 352008510)
83. Restoration of acute insulin response in T2DM subjects 1month after biliopancreatic diversion. Briatore L, Salani B, Andraghetti G, Danovaro C, Sferrazzo E, Scopinaro N, Adami GF, Maggi D, Cordera R, Obesity (Silver Spring) 2008 16 77 81 10.1038/oby.2007.9 (Pubitemid 351271953)
84. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Valverde I, Puente J, Martin-Duce A, Molina L, Lozano O, Sancho V, Malaisse WJ, Villanueva-Penacarrillo ML, Obes Surg 2005 15 387 397 10.1381/0960892053576613 15826475 (Pubitemid 40463608)
85. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE, Pharmacogenetics 1995 5 121 141 10.1097/00008571-199506000-00001 7550364
86. Blum K, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman ER, Gold M, Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery J Genet Syndr, Gene Ther 2011 2011
87. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Konner AC, Hess S, Tovar S, Mesaros A, Sanchez-Lasheras C, Evers N, Verhagen LA, Bronneke HS, Kleinridders A, Hampel B, et al. Cell Metab 2011 13 720 728 10.1016/j.cmet.2011.03.021 21641553